Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20438384 | 1.00 | ADH1B (0.39) | ADH1BADH1CADH1A | |
| SCHEMBL19754763 | 0.93 | ADH1A (0.44) | ADH1BADH1CADH1A | |
| SCHEMBL15221572 | 0.90 | ADH1A (0.48) | ADH1BADH1CADH1A | |
| SCHEMBL20245189 | 0.88 | ADH1B (0.33) | ADH1BADH1CADH1A | |
| SCHEMBL9551174 | 0.87 | ADH1A (0.52) | ADH1BADH1CADH1A | |
| SCHEMBL18841464 | 0.87 | ADH1A (0.52) | ADH1BADH1CADH1A | |
| SCHEMBL296264 | 0.87 | ADH1A (0.52) | ADH1BADH1CADH1A | |
| SCHEMBL12790402 | 0.86 | SHBG (0.36) | ADH1BADH1CADH1A | |
| SCHEMBL13397245 | 0.86 | ADH1B (0.32) | ADH1BADH1CADH1A | |
| SCHEMBL731265 | 0.84 | ADH1A (0.50) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130074216-A1 | TOMATO CATECHOL-O-METHYLTRANSFERASE SEQUENCES AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8133486-B2 | Method and composition for altering a B cell mediated pathology | MMRGLOBAL, INC. (US) | 2012-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | PAICS, UGT1A1, CYP7A1 | ADH1B 764/4885ADH1C 449/4885ADH1A 200/4885 |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ADH1B 4710/4885ADH1C 4660/4885ADH1A 4667/4885 |
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | HAVCR2, EIF2AK2, MAVS | ADH1B 2952/4885ADH1C 2731/4885ADH1A 2934/4885 |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | ADH1B 2722/4885ADH1C 4593/4885ADH1A 4610/4885 |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ADH1B 4021/4885ADH1C 2711/4885ADH1A 3361/4885 |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | PDE10A, PDE1B, PDE9A | ADH1B 1150/4885ADH1C 145/4885ADH1A 563/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ADH1B 4710/4885ADH1C 4660/4885ADH1A 4667/4885 |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | NLK, DCLK2, DLK1 | ADH1B 1265/4885ADH1C 1313/4885ADH1A 2297/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | ADH1B 4021/4885ADH1C 2711/4885ADH1A 3361/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ADH1B 4021/4885ADH1C 2711/4885ADH1A 3361/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ADH1B 4021/4885ADH1C 2711/4885ADH1A 3361/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ADH1B 3750/4885ADH1C 2715/4885ADH1A 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.